Whales with a lot of money to spend have taken a noticeably bearish stance on Moderna.
Looking at options history for Moderna MRNA we detected 32 trades.
If we consider the specifics of each trade, it is accurate to state that 25% of the investors opened trades with bullish expectations and 62% with bearish.
From the overall spotted trades, 14 are puts, for a total amount of $2,567,424 and 18, calls, for a total amount of $2,513,783.
Expected Price Movements
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $22.5 and $120.0 for Moderna, spanning the last three months.
Volume & Open Interest Development
In terms of liquidity and interest, the mean open interest for Moderna options trades today is 2606.31 with a total volume of 17,772.00.
In the following chart, we are able to follow the development of volume and open interest of call and put options for Moderna's big money trades within a strike price range of $22.5 to $120.0 over the last 30 days.
Moderna Option Activity Analysis: Last 30 Days
Noteworthy Options Activity:
Symbol | PUT/CALL | Trade Type | Sentiment | Exp. Date | Ask | Bid | Price | Strike Price | Total Trade Price | Open Interest | Volume |
---|---|---|---|---|---|---|---|---|---|---|---|
MRNA | PUT | SWEEP | NEUTRAL | 12/18/26 | $69.0 | $67.25 | $69.0 | $100.00 | $1.2M | 951 | 260 |
MRNA | CALL | SWEEP | BEARISH | 01/15/27 | $8.3 | $8.2 | $8.2 | $55.00 | $607.6K | 1.5K | 1.8K |
MRNA | CALL | SWEEP | BEARISH | 01/15/27 | $8.35 | $8.2 | $8.2 | $55.00 | $392.8K | 1.5K | 677 |
MRNA | CALL | SWEEP | BULLISH | 07/18/25 | $10.1 | $9.95 | $10.1 | $25.00 | $301.9K | 42 | 302 |
MRNA | PUT | SWEEP | BULLISH | 12/18/26 | $69.3 | $69.0 | $69.0 | $100.00 | $276.0K | 951 | 40 |
About Moderna
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 40 mRNA development candidates in clinical development as of September 2024. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
After a thorough review of the options trading surrounding Moderna, we move to examine the company in more detail. This includes an assessment of its current market status and performance.
Current Position of Moderna
- With a volume of 5,836,707, the price of MRNA is down -1.13% at $31.51.
- RSI indicators hint that the underlying stock is currently neutral between overbought and oversold.
- Next earnings are expected to be released in 3 days.
Expert Opinions on Moderna
A total of 5 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $54.4.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. Click here for access. * Maintaining their stance, an analyst from Morgan Stanley continues to hold a Equal-Weight rating for Moderna, targeting a price of $38. * An analyst from Goldman Sachs has decided to maintain their Buy rating on Moderna, which currently sits at a price target of $99. * Reflecting concerns, an analyst from Goldman Sachs lowers its rating to Neutral with a new price target of $51. * Consistent in their evaluation, an analyst from B of A Securities keeps a Underperform rating on Moderna with a target price of $34. * Consistent in their evaluation, an analyst from Evercore ISI Group keeps a In-Line rating on Moderna with a target price of $50.
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Moderna with Benzinga Pro for real-time alerts.
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.